Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 3/20 | 0.72 |
| ▸ | EGFR | P00533 | 2/20 | 0.68 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 5/20 | 0.59 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.57 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26313600 | 0.92 | MLYCD (0.64) | MLYCDEGFRERBB2TP53HPGD | |
| SCHEMBL4489409 | 0.92 | MLYCD (0.64) | MLYCDEGFRERBB2TP53HPGD | |
| SCHEMBL7967022 | 0.92 | MLYCD (0.64) | MLYCDEGFRERBB2TP53HPGD | |
| SCHEMBL26314066 | 0.92 | MLYCD (0.64) | MLYCDEGFRERBB2TP53HPGD | |
| SCHEMBL5543209 | 0.90 | MLYCD (0.62) | MLYCDEGFRERBB2TP53HPGD | |
| SCHEMBL10777907 | 0.90 | MLYCD (0.62) | MLYCDEGFRERBB2TP53HPGD | |
| SCHEMBL7454658 | 0.90 | MLYCD (0.62) | MLYCDEGFRERBB2TP53HPGD | |
| SCHEMBL21077862 | 0.90 | MLYCD (0.62) | MLYCDEGFRERBB2TP53HPGD | |
| SCHEMBL10488234 | 0.90 | MLYCD (0.62) | MLYCDEGFRERBB2TP53HPGD | |
| SCHEMBL15221192 | 0.90 | MLYCD (0.67) | MLYCDEGFRERBB2TP53HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3068762-B1 | METAL COMPLEXES AND METHODS OF TREATMENT | COLLABORATIVE MEDICINAL DEV LLC (US) | 2019-12-25 | — | — | EP | claimed |
| WO-2018222572-A1 | NON-COVALENT DERIVATIVES AND METHODS OF TREATMENT | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2018-12-06 | — | — | WO | claimed |
| US-20160271175-A1 | Metal Complexes and Methods of Treatment | PROCYPRA THERAPEUTICS LLC (US) | 2016-09-22 | — | — | US | claimed |
| EP-3068762-A2 | METAL COMPLEXES AND METHODS OF TREATMENT | Collaborative Medicinal Development, LLC (US) | 2016-09-21 | — | — | EP | claimed |
| WO-2015070177-A2 | METAL COMPLEXES AND METHODS OF TREATMENT | COLLABORATIVE MEDICINAL DEVELOPMENT, LLC (US) | 2015-05-14 | — | — | WO | claimed |
| US-11266686-B2 | Metal complexes and methods of treatment | PROCYPRA THERAPEUTICS LLC (US) | 2022-03-08 | — | — | US | disclosed |
| EP-3068762-B1 | METAL COMPLEXES AND METHODS OF TREATMENT | COLLABORATIVE MEDICINAL DEV LLC (US) | 2019-12-25 | — | — | EP | disclosed |
| WO-2018222572-A1 | NON-COVALENT DERIVATIVES AND METHODS OF TREATMENT | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2018-12-06 | — | — | WO | disclosed |
| US-20160271175-A1 | Metal Complexes and Methods of Treatment | PROCYPRA THERAPEUTICS LLC (US) | 2016-09-22 | — | — | US | disclosed |
| EP-3068762-A2 | METAL COMPLEXES AND METHODS OF TREATMENT | Collaborative Medicinal Development, LLC (US) | 2016-09-21 | — | — | EP | disclosed |
| WO-2015070177-A2 | METAL COMPLEXES AND METHODS OF TREATMENT | COLLABORATIVE MEDICINAL DEVELOPMENT, LLC (US) | 2015-05-14 | — | — | WO | disclosed |
| EP-0492823-A2 | Perfluorinated t-amino cyclic ethers | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1992-07-01 | — | — | EP | disclosed |
| US-4665410-A | THERMOGRAPHY | RICOH COMPANY, LTD. (JP) | 1987-05-12 | — | — | US | disclosed |
| US-4663641-A | LEUCO DYES; DECOLORIZING AGENTS, PIPERAZINE COMPOUND; AMIDES AND TERTIARY AMINES | RICOH COMPANY, LTD. (JP) | 1987-05-05 | — | — | US | disclosed |
| US-4613878-A | DECOLORIZING AGENT COMPRISING AROMATIC DIAMIDE OR PIPERAZINE DERIVATIVE, HAVING TWO ACYLAMINO GROUPS | RICOH COMPANY, LTD. (JP) | 1986-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11266686-B2 | Metal complexes and methods of treatment | NLN, PNMT, BDNF | MLYCD 1726/4885EGFR 1567/4885ERBB2 1196/4885 |
| US-20160271175-A1 | Metal Complexes and Methods of Treatment | NLN, PNMT, BDNF | MLYCD 1726/4885EGFR 1567/4885ERBB2 1196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.